Stock·NASDAQ·Consumer Cyclical
Crocs, Inc. (CROX)
- Market cap
- $5.70B
- P/E
- 10.45
- Dividend yield
- None
- Street target
- $147.50median of 15 analysts
- 52-week range
- $73.21 $141.28
CROX stock forecast today
Where CROX stands today, and what CleaRank Financial AI makes of it.
CROX at a glance
Crocs, Inc. (CROX): Buy, 69/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($108.93 and $119.75).
- Earnings CROX beat estimates in 8 of its last 8 quarters, yet fell the next day after 5 of those beats.
- Insiders Insiders sold $11.6M and bought $1.2M over the last 18 months.
- Valuation P/E of 10.4 against 20.8 for the Consumer Cyclical sector: a discount to peers (-50%).
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Crocs, Inc. (CROX) Buy, with a model score of 69/100.
The trend lifts the score most: the price is 9.11% above its 200-day average, and the 50-day average is 9.94% above the 200-day. The 50-day average stands at $119.75 and the 200-day at $108.93. Over the past year the price rose 43.50%.
Only on CleaRank
Figures we compute ourselves from CROX's own price, earnings and insider-filing history. Tap one to see it in context.
CROX stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $118.85 is 0.8% below the 50-day simple moving average of $119.75.Price above its 200-day average ›
The price is 9.1% above the 200-day simple moving average of $108.93.50-day average above the 200-day ›
The 50-day average ($119.75) is 9.9% above the 200-day average ($108.93), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 67% of its 52-week range, between $73.21 and $141.28.
CROX share price
Pick a period: each tab shows how far CROX has moved over it, to the last close.
Today's trading
Where CROX sits inside today's range and its 52-week range.
CROX fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 10.45 is 49.8% below the Consumer Cyclical median of 20.8.P/S below the sector median ›
The price-to-sales ratio of 1.41 is 25.8% below the sector median of 1.9.Profitable over the last 12 months ›
Net income over the last 12 months was $593.4M on revenue of $4.1B, a net margin of 14.6%.Beat estimates in most recent reports ›
CROX beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for CROX.
As of October 26, 2026, CROX trades at $118.85, with a market value of $5.70B and a P/E ratio of 10.45.
What the numbers say
CleaRank Financial AI's reading of CROX's valuation, growth and risks.
Crocs, Inc. (CROX) carries a trailing P/E of 10.45, which is 49.8% under the Consumer Cyclical median of 20.8. The peer comparison on this page labels that a discount to peers. Measured against sales, CROX changes hands at 1.41 times, 25.8% below the sector median of 1.9. Its trailing earnings stand at $11.41 per share.
With revenue growth of 2.60%, CROX is 4.6 percentage points slower than the sector median of 7.2%. Profitability shows a net margin of 14.64% and an operating margin of 24.22%, with a return on equity of 42.30%, above the sector median of 12.4%. The balance sheet rounds out the picture, with debt-to-equity of 1.22.
EPS of $4.55 versus the $4.35 analysts expected made the July 30, 2026 report a beat of 4.60%. The market agreed: the stock rose 3.52% the following session.
Across its last 8 reports, CROX beat the estimate every time, but beats have not guaranteed gains: the stock fell the next day after 5 of them. The consensus EPS estimate stands at $13.97 for this fiscal year and $15.01 for next, growth of 11.6% for the current year.
CROX typically moves about 2.49% on an average day, and its beta against the S&P 500 is 1.56. The stock is 15.88% below its 52-week high of $141.28. Over the last 18 months insiders sold $11.6M of stock and bought $1.2M. Insider sales are often planned ahead or made to cover taxes on vesting shares, so they carry less weight than open-market purchases.
CROX against the Consumer Cyclical sector
How CROX compares with the median Consumer Cyclical stock CleaRank tracks.
Price to earnings vs sector: CROX trades at a notable discount to sector peers (-50%), which may indicate undervaluation or specific company headwinds.
Return vs SPY: Since May 14, 2025, CROX has gained 0.5% against a gain of 30.2% for SPY.
Performance against SPY
CROX and the S&P 500 (SPY) over the same days.
Revenue and earnings
How much CROX sells, and how much of it becomes profit.
Revenue growth: Revenue fell 1.5% in FY2025 to $4.0B, from $4.1B a year earlier.
Profit margin: The net margin was -2.0% in FY2025, down from 23.2% the year before.
Loss-making: CROX lost $81.2M in FY2025.
Earnings reality check
Did CROX beat what analysts expected, and how did the stock react?
Earnings record: CROX beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 5 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | $4.35 | $4.55 | +4.60% | +3.52% | +8.51% |
| Apr 30, 2026after close | $2.79 | $2.99 | +7.17% | +1.86% | +2.06% |
| Feb 12, 2026after close | $1.91 | $2.29 | +19.90% | -1.60% | +1.60% |
| Oct 30, 2025after close | $2.36 | $2.92 | +23.73% | -1.03% | -4.98% |
| Aug 7, 2025after close | $4.02 | $4.23 | +5.22% | +1.14% | +12.96% |
| May 8, 2025after close | $2.49 | $3.00 | +20.48% | -0.80% | +5.98% |
| Feb 13, 2025after close | $2.26 | $2.52 | +11.50% | -1.47% | -2.23% |
| Oct 29, 2024after close | $3.11 | $3.60 | +15.76% | -2.31% | -5.70% |
As of October 26, 2026, CROX has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 5 of those beats; its latest report, on July 30, 2026, came in 4.60% above the estimate and the stock moved +3.52% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
CROX AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/2RSI not overbought or oversold ›
The 14-day RSI is 48.2, in neutral territory.RSI above 50 ›
An RSI of 48.2 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.
CleaRank Financial AI analysis of CROX
The score, the reasoning behind it, and what could move the price next.
CROX shows a mixed trend. The stock is trading at $118.85, which leaves it 0.76% below its 50-day average of $119.75, yet 9.11% above its 200-day average of $108.93. Inside its 52-week range of $73.21 to $141.28, the price stands at 67% of the range and 15.88% below the high.
A recent pullback sits inside a stronger longer record: the price fell 5.78% over the past month, fell 11.66% over the past three months and rose 43.50% over the past year.
Earnings beat ›
The July 30, 2026 report beat the EPS estimate by 4.60%, and the share price rose 3.52% in the first session after it.
Source: Earnings report, July 30, 2026Analyst upgrade ›
Barclays upgraded it to Overweight from Equal-Weight on October 15, 2026.
Source: Analyst action, Barclays, October 15, 2026Analyst upgrade ›
Piper Sandler upgraded it to Overweight from Neutral on June 26, 2026.
Source: Analyst action, Piper Sandler, June 26, 2026
- The two closest levels matter most: the 20-day EMA at $119.66 above the price and the 200-day SMA at $108.93 below it.
- In the first session after the July 30, 2026 report, the share price climbed 3.52%. CROX has beaten estimates in 8 of the last 8 reports.
The trend is mixed: CROX is above its 200-day average at $108.93 but below its 50-day average at $119.75. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. The nearest levels are the 200-day SMA at $108.93 below and the 20-day EMA at $119.66 above.
Technical indicators
Momentum and trend for CROX, from its daily closes.
As of October 26, 2026, with CROX at $118.85, its 14-day RSI is 48.2 (neutral territory), its 50-day simple moving average is $119.75 and its 200-day is $108.93.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What CROX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, CROX's 1-year correlation of daily returns is +0.31 with S&P 500 (SPY), +0.24 with Nasdaq 100 (QQQ), +0.04 with Bitcoin (BTC) and -0.02 with gold (XAU).
CROX price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
8 of 15 analysts rate it a buy or strong buy, 6 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $147.50 is 24.1% above the price.More buy ratings than three months ago ›
8 of 15 rate it a buy now, against 7 of 15 three months ago.
CROX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 15, 2026 | Barclays | Upgrade | Overweight |
| Jul 31, 2026 | UBS | Maintains | Neutral |
| Jul 31, 2026 | Barclays | Maintains | Equal-Weight |
| Jul 23, 2026 | B of A Securities | Maintains | Buy |
| Jul 20, 2026 | Seaport Global | Maintains | Buy |
| Jun 26, 2026 | Piper Sandler | Upgrade | Overweight |
As of October 26, 2026, 15 Wall Street analysts cover CROX: 8 rate it a buy or strong buy, 6 a hold and 1 a sell or strong sell. Their 12-month price targets range from $95.00 to $163.00. The median CROX price target is $147.50, 24.1% above the price of $118.85.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CROX trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CROX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CROX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CROX tends to move, against the market and on its own.
CROX price history and drawdowns
CROX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 2.49% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 73.2%, from November 2021 to June 2022; the price is still 34.2% below that peak.Most 1-year holds ended higher ›
72% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $154,753, against $42,015 in the S&P 500 (SPY).
CROX Drawdowns & Recovery
As of October 26, 2026, CROX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -73.2% (November 2021 to June 2022); it is still 34.2% below that peak, and 72% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CROX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CROX beat the S&P 500 over this period: $154,753 against $42,015.
A $10,000 investment in CROX in October 2016 would be worth about $154,753 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CROX, and which have not.
Strongest month, November: an average of +11.10%, up in 8 of 10 years.
Weakest month, March: an average of -3.30%, up in 4 of 10 years.
This month, October: has averaged +4.10%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CROX's strongest calendar month has been November (average +11.10%, up in 8 of 10 years) and its weakest March (average -3.30%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
CROX stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CROX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in CROX today could grow to about $15,411 by 2030 in the base case, with a 90th-percentile outcome near $55,517 and a 10th-percentile outcome around $4,278. Projections are statistical simulations, not guarantees.
CROX Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $183 for CROX by 2030 in the base case, from $119 today (1.5x over 4 years). The 10th-percentile path ends near $50.84. These are outcomes of a Monte Carlo simulation run on CROX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $69.77 | $132 | $251 | |
| 2028 | $59.61 | $148 | $365 | |
| 2029 | $54.18 | $164 | $499 | |
| 2030 | $50.84 | $183 | $660 |
Method: a lognormal simulation of CROX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. CROX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. How the simulation works
CROX insider trading
What the people running the company have bought and sold.
CROX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $1.2M on the open market and sold $11.6M.
As of October 26, 2026, CROX insiders reported 7 open-market sales worth $11.6M and 6 open-market purchases worth $1.2M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Beth Janell Kaplan
Director
|
Buy | 885 | $99.2K |
| Sep 15, 2026 | Thomas J Smach
Director
|
Buy | 680 | $75.8K |
| Sep 10, 2026 | Thomas J Smach
Director
|
Buy | 4.0K | $437.5K |
| Aug 10, 2026 | Andrew Vivian Rees
Chief Executive Officer
|
Sell | 30.0K | $4.2M |
| Aug 4, 2026 | Andrew Vivian Rees
Chief Executive Officer
|
Option | 200.0K | $1.4M |
| Jun 9, 2026 | Ian M Bickley
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | Ronald L Frasch
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | Charisse Ford Hughes
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | Beth Janell Kaplan
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | John B Replogle
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | Thomas J Smach
Director
|
Grant | 4.1K | - |
| Jun 9, 2026 | Neeraj Tolmare
Director
|
Grant | 2.3K | - |
| Jun 9, 2026 | Douglas J Treff
Director
|
Grant | 2.5K | - |
| Jun 5, 2026 | Andrew Vivian Rees
Chief Executive Officer
|
Sell | 32.7K | $3.9M |
| May 22, 2026 | Ronald L Frasch
Director
|
Grant | 500 | - |
| Mar 10, 2026 | Rupert George Campbell
Officer
|
Grant | 38.7K | - |
| Mar 10, 2026 | Anne Mehlman
Officer
|
Grant | 68.3K | - |
| Mar 10, 2026 | Patraic Reagan
Chief Financial Officer
|
Grant | 44.2K | - |
| Mar 10, 2026 | Andrew Vivian Rees
Chief Executive Officer
|
Grant | 207.9K | - |
| Mar 10, 2026 | Terence Reilly
Officer
|
Grant | 44.2K | - |
| Feb 20, 2026 | Anne Mehlman
Officer
|
Sell | 12.1K | $1.2M |
| Feb 20, 2026 | Thomas J Smach
Director
|
Sell | 5.0K | $496.3K |
| Feb 13, 2026 | Thomas J Smach
Director
|
Sell | 5.0K | $492.1K |
| Nov 20, 2025 | Andrew Vivian Rees
Chief Executive Officer
|
Grant | 40.0K | - |
| Nov 11, 2025 | John B Replogle
Director
|
Buy | 3.0K | $223.5K |
| Sep 22, 2025 | Patraic Reagan
Chief Financial Officer
|
Grant | 45.4K | - |
| Aug 12, 2025 | Susan L Healy
Chief Financial Officer
|
Buy | 2.0K | $153.1K |
| Aug 8, 2025 | John B Replogle
Director
|
Buy | 3.3K | $250.1K |
| Jun 10, 2025 | Ian M Bickley
Director
|
Grant | 2.9K | - |
| Jun 10, 2025 | Ronald L Frasch
Director
|
Grant | 1.5K | - |
| Jun 10, 2025 | Charisse Ford Hughes
Director
|
Grant | 2.9K | - |
| Jun 10, 2025 | Beth Janell Kaplan
Director
|
Grant | 1.5K | - |
| Jun 10, 2025 | John B Replogle
Director
|
Grant | 2.9K | - |
| Jun 10, 2025 | Thomas J Smach
Director
|
Grant | 5.0K | - |
| Jun 10, 2025 | Neeraj Tolmare
Director
|
Grant | 2.9K | - |
| Jun 10, 2025 | Douglas J Treff
Director
|
Grant | 3.1K | - |
| May 12, 2025 | Ian M Bickley
Director
|
Sell | 3.0K | $352.8K |
| May 9, 2025 | Thomas J Smach
Director
|
Sell | 9.1K | $1.0M |
Source: TwelveData, from SEC Form 4 filings
CROX stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.